This study is testing whether an immunotherapy treatment called PVX108 can help children with peanut allergy safely tolerate more peanut protein. The trial involves 90 children and adolescents aged 4-11 years who have confirmed peanut allergy. Researchers will measure how much pe…
Phase: PHASE2 • Sponsor: Aravax Pty Ltd • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC